Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
about
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three casesPembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patientsPembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
P2860
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Cost Effectiveness of Pembroli ...... of PD-L1 in the United States.
@en
type
label
Cost Effectiveness of Pembroli ...... of PD-L1 in the United States.
@en
prefLabel
Cost Effectiveness of Pembroli ...... of PD-L1 in the United States.
@en
P2093
P2860
P1433
P1476
Cost Effectiveness of Pembroli ...... of PD-L1 in the United States
@en
P2093
Frank Xiaoqing Liu
James Pellissier
Ruifeng Xu
Thomas Burke
Vamsidhar Velcheti
Yanyan Lou
P2860
P2888
P304
P356
10.1007/S40273-017-0527-Z
P50
P577
2017-08-01T00:00:00Z